Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of encorafenib for BRAF-mutated advanced melanoma.

Current opinion in oncology - 1 Mar 2018

Koelblinger Peter, Thuerigen Olaf, Dummer Reinhard

Abstract excerpt

PURPOSE OF REVIEW: To describe the pharmacological properties, preclinical and clinical data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-inhibitor encorafenib (LGX818) and to compare these with established BRAF-inhibitors in the treatment of locally advanced or metastatic melanoma. RECENT FINDINGS: Encorafenib has shown improved efficacy in the treatment of metastatic melanoma in comparison...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carbamates
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Randomized Controlled Trials as Topic

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 29356698
DOI: 10.1097/CCO.0000000000000426
PMCID: PMC5815646

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of encorafenib for BRAF-mutated advanced melanoma.PMID 29356698Read ↗

An evaluation of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

Preclinical discovery and clinical development of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

An overview of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.Semantic proximity Read ↗

The discovery and development of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.Semantic proximity Read ↗

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.Semantic proximity Read ↗

In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.Semantic proximity Read ↗

Encorafenib and Binimetinib: First Global Approvals.Semantic proximity Read ↗

Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?Semantic proximity Read ↗

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.Semantic proximity Read ↗

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.